[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:duchenne-muscular-dystrophy":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":261,"states":270},"Duchenne Muscular Dystrophy",41,31,[8,16,23,29,36,43,49,54,60,67,73,79,86,92,98,104,109,115,121,127,133,139,145,151,157,163,169,175,181,186,192,198,205,212,217,223,229,235,242,248,254],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04626674","A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort",[12],"Phase 1","RECRUITING","2026-08-26T02:18:57.189473Z","2026-07-05T05:32:16.793638Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07160634","A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)",[20],"Phase 3","2026-08-26T02:16:38.053590Z","2026-06-04T01:30:07.901496Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07608432","Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)",[20],"2026-08-26T02:19:03.581490Z","2026-05-29T15:36:40.225735Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT07429240","PBGENE-DMD Phase 1\u002F2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)",[33],"Phase 1\u002FPhase 2","2026-08-26T02:16:34.792807Z","2026-05-13T02:55:06.704813Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT07287189","Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients",[40],"Phase 2","2026-08-26T02:18:55.570428Z","2026-05-05T02:43:28.877632Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06138639","A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)",[33],"2026-08-26T02:18:15.214990Z","2026-05-05T02:43:28.676613Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":14,"content_modified":53},"NCT06692426","Trial of Cell Based Therapy for DMD",[12],"2026-05-05T02:43:28.180268Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04906460","Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)",[33],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:28.128996Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT03373968","Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study",[64],"Phase 2\u002FPhase 3","2026-08-26T02:17:15.156099Z","2026-05-05T02:43:27.827220Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06224660","Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy",[12],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:27.631699Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06290713","Vasodilator and Exercise Study for DMD (VASO-REx)",[40],"2026-08-26T02:16:01.910993Z","2026-05-05T02:43:26.741416Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":84,"content_modified":85},"NCT05412394","Once Weekly Infant Corticosteroid Trial for DMD",[83],"Phase 4","2026-08-26T02:19:19.975067Z","2026-05-05T02:43:26.676741Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT05996003","NS-089\u002FNCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)",[40],"2026-08-26T02:18:46.948970Z","2026-05-05T02:35:31.916688Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT06817382","A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)",[12],"2026-08-26T02:17:57.117858Z","2026-05-05T02:35:31.904026Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT07127978","A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy",[],"2026-08-26T02:15:21.365312Z","2026-05-13T02:55:06.655936Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":65,"content_modified":108},"NCT07092540","The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy",[],"2026-05-13T02:55:06.653457Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06925269","DMD Voice: Qualitative Interviews With Patients and Caregivers",[],"2026-08-26T02:16:00.194860Z","2026-05-13T02:55:06.591766Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT06839469","Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders",[],"2026-08-26T02:15:37.042762Z","2026-05-13T02:55:06.583259Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06564974","Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT",[],"2026-08-26T02:18:13.438956Z","2026-05-13T02:55:06.510409Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT06124196","Wearable Technology to Evaluate Hyperglycemia and HRV in DMD",[],"2026-08-26T02:18:24.494016Z","2026-05-13T02:55:06.417536Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06093100","Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim",[],"2026-08-26T02:19:12.219640Z","2026-05-13T02:55:06.407938Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT05016908","Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy",[],"2026-08-26T02:18:46.137046Z","2026-05-13T02:55:06.278359Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT01484678","Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy",[],"2026-08-26T02:18:52.966503Z","2026-05-13T02:55:06.074346Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT07674758","Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials",[],"2026-08-26T02:18:44.395098Z","2026-07-05T03:45:20.436420Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT07609394","Duchenne Electronic Health Record Study",[],"2026-08-26T02:18:16.220328Z","2026-05-29T15:36:40.227967Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT05019625","Biomarker Development for Muscular Dystrophies",[],"2026-08-26T02:15:36.077529Z","2026-05-13T02:55:06.278851Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT02069756","The Duchenne Registry",[],"2026-08-26T02:15:24.145250Z","2026-05-13T02:55:06.081909Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT00390104","Molecular Analysis of Patients With Neuromuscular Disease",[],"2026-08-26T02:15:50.539717Z","2026-05-13T02:55:06.035661Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":155,"content_modified":185},"NCT06539169","FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases",[],"2026-05-13T02:55:06.551987Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT07172971","Sodium\u002FGlucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy",[12],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:27.479077Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT07332013","Urinary Titin Biomarker in DMD",[],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:26.920539Z",{"nct_id":199,"title":200,"phases":201,"status":202,"updated_at":203,"content_modified":204},"NCT07642635","Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy",[33],"NOT_YET_RECRUITING","2026-08-26T02:15:20.225313Z","2026-06-14T18:39:22.260654Z",{"nct_id":206,"title":207,"phases":208,"status":209,"updated_at":210,"content_modified":211},"NCT05967351","A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:18:17.007929Z","2026-06-16T05:54:08.092098Z",{"nct_id":213,"title":214,"phases":215,"status":209,"updated_at":34,"content_modified":216},"NCT06606340","A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice",[],"2026-06-16T05:54:07.762469Z",{"nct_id":218,"title":219,"phases":220,"status":209,"updated_at":221,"content_modified":222},"NCT06491927","Long Term Follow-up for RGX-202",[],"2026-08-26T02:19:29.922117Z","2026-06-16T05:54:07.755349Z",{"nct_id":224,"title":225,"phases":226,"status":209,"updated_at":227,"content_modified":228},"NCT06270719","An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy",[],"2026-08-26T02:17:10.213717Z","2026-06-16T05:54:07.721404Z",{"nct_id":230,"title":231,"phases":232,"status":209,"updated_at":233,"content_modified":234},"NCT03836300","Parent and Infant Inter(X)Action Intervention (PIXI)",[],"2026-08-26T02:18:48.678868Z","2026-06-16T05:54:07.971455Z",{"nct_id":236,"title":237,"phases":238,"status":239,"updated_at":240,"content_modified":241},"NCT05693142","AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)",[64],"ACTIVE_NOT_RECRUITING","2026-08-03T01:56:45.025842Z","2026-05-05T02:43:26.742492Z",{"nct_id":243,"title":244,"phases":245,"status":239,"updated_at":246,"content_modified":247},"NCT05683379","AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD",[],"2026-08-03T03:37:48.267540Z","2026-05-13T02:55:06.369940Z",{"nct_id":249,"title":250,"phases":251,"status":239,"updated_at":252,"content_modified":253},"NCT03655223","Early Check: Expanded Screening in Newborns",[],"2026-08-03T03:53:57.297126Z","2026-06-16T05:54:07.977837Z",{"nct_id":255,"title":256,"phases":257,"status":258,"updated_at":259,"content_modified":260},"NCT05635266","Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives",[],"UNKNOWN","2026-08-03T02:15:56.082035Z","2026-05-13T02:55:06.368062Z",[262,266],{"biomarker":263,"count":264,"slug":265},"DMD Gene",11,"dmd-gene",{"biomarker":267,"count":268,"slug":269},"Dystrophin",3,"dystrophin",[271,275,279,282,286,289,292,295,298,302,306,310,313,317,320,323,326,329,333,337,340,343,346,349],{"state":272,"count":273,"slug":274},"California",15,"california",{"state":276,"count":277,"slug":278},"Arkansas",14,"arkansas",{"state":280,"count":277,"slug":281},"Ohio","ohio",{"state":283,"count":284,"slug":285},"Virginia",13,"virginia",{"state":287,"count":264,"slug":288},"Illinois","illinois",{"state":290,"count":264,"slug":291},"North Carolina","north-carolina",{"state":293,"count":264,"slug":294},"Pennsylvania","pennsylvania",{"state":296,"count":264,"slug":297},"Texas","texas",{"state":299,"count":300,"slug":301},"Massachusetts",10,"massachusetts",{"state":303,"count":304,"slug":305},"Florida",9,"florida",{"state":307,"count":308,"slug":309},"New York",8,"new-york",{"state":311,"count":308,"slug":312},"Tennessee","tennessee",{"state":314,"count":315,"slug":316},"District of Columbia",7,"district-of-columbia",{"state":318,"count":315,"slug":319},"Georgia","georgia",{"state":321,"count":315,"slug":322},"Missouri","missouri",{"state":324,"count":315,"slug":325},"Oregon","oregon",{"state":327,"count":315,"slug":328},"Washington","washington",{"state":330,"count":331,"slug":332},"Colorado",6,"colorado",{"state":334,"count":335,"slug":336},"Iowa",5,"iowa",{"state":338,"count":335,"slug":339},"Kansas","kansas",{"state":341,"count":268,"slug":342},"Connecticut","connecticut",{"state":344,"count":268,"slug":345},"Indiana","indiana",{"state":347,"count":268,"slug":348},"Michigan","michigan",{"state":350,"count":268,"slug":351},"Wisconsin","wisconsin"]